Neurocritical Care

, Volume 16, Issue 3, pp 399–405 | Cite as

Drainage Efficiency with Dual Versus Single Catheters in Severe Intraventricular Hemorrhage

  • Holly E. Hinson
  • Eric Melnychuk
  • John Muschelli
  • Daniel F. Hanley
  • Issam A. Awad
  • Wendy C. Ziai
Original Article



Little is known about the efficacy of single versus dual extraventricular drain (EVD) use in intraventricular hemorrhage (IVH), with and without thrombolytic therapy.


Post-hoc analysis of seven patients with dual bilateral EVDs from two multicenter trials involving 100 patients with IVH, and spontaneous intracerebral hemorrhage (ICH) volume <30 ml requiring emergency external ventricular drainage. Seven “control” patients with single catheters were matched by IVH volume and distribution and treatment assignment. Head CT scans were obtained daily during intraventricular injections for quantitative determination of IVH volume.


Median [min–max] age of the 14 subjects was 56 [40–73] years. Median duration of EVD was 7.9 days (single catheter group) versus 12.2 days (dual catheter group) (P = 0.34). Baseline median IVH volume was not significantly different between groups (75.4 ml [22.4–105.1]—single EVD vs. 84.5 ml [42.0–132.0]—dual EVD; P = 0.28). Comparing the change in IVH volume on time-matched CT scans during dual EVD use, the median decrease in IVH volume in dual catheter patients was significantly larger (52.1 [31.7–81.1] ml) versus single catheter patients (34.5 [13.1–73.9] ml) (P = 0.004). There was a trend to greater decrease in IVH volume during dual EVD use in both rt-PA (P = 0.9) and placebo-treated (P = 0.11) subgroups.


The decision to place dual EVDs is generally reserved for large IVH (>40 ml) with casting and mass effect. The use of dual simultaneous catheters may increase clot resolution with or without adjunctive thrombolytic therapy.


External ventricular drain Intraventricular hemorrhage Thrombolysis 


  1. 1.
    Vereecken KK, Van Havenbergh T, De Beuckelaar W, Parizel PM, Jorens PG. Treatment of intraventricular hemorrhage with intraventricular administration of recombinant tissue plasminogen activator. A clinical study of 18 cases. Clin Neurol Neurosurg. 2006;108(5):451–5.PubMedCrossRefGoogle Scholar
  2. 2.
    Coplin WM, Vinas FC, Agris JM, et al. A cohort study of the safety and feasibility of intraventricular urokinase for nonaneurysmal spontaneous intraventricular hemorrhage. Stroke. 1998;29(8):1573–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Findlay JM, Grace MG, Weir BK. Treatment of intraventricular hemorrhage with tissue plasminogen activator. Neurosurgery. 1993;32(6):941–7. (discussion 947).PubMedCrossRefGoogle Scholar
  4. 4.
    Andrews CO, Engelhard HH. Fibrinolytic therapy in intraventricular hemorrhage. Ann Pharmacother. 2001;35(11):1435–48.PubMedCrossRefGoogle Scholar
  5. 5.
    Naff NJ, Carhuapoma JR, Williams MA, et al. Treatment of intraventricular hemorrhage with urokinase : effects on 30-Day survival. Stroke. 2000;31(4):841–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Staykov D, Huttner HB, Lunkenheimer J, et al. Single versus bilateral external ventricular drainage for intraventricular fibrinolysis in severe ventricular haemorrhage. J Neurol Neurosurg Psychiatry. 2010;81(1):105–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Kothari RU, Brott T, Broderick JP, et al. The ABCs of measuring intracerebral hemorrhage volumes. Stroke. 1996;27(8):1304–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Graeb DA, Robertson WD, Lapointe JS, Nugent RA, Harrison PB. Computed tomographic diagnosis of intraventricular hemorrhage. Etiology and prognosis. Radiology. 1982;143(1):91–6.PubMedGoogle Scholar
  9. 9.
    Pang D, Sclabassi RJ, Horton JA. Lysis of intraventricular blood clot with urokinase in a canine model: Part 1. Canine intraventricular blood cast model. Neurosurgery. 1986;19(4):540–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Mayfrank L, Kissler J, Raoofi R, et al. Ventricular dilatation in experimental intraventricular hemorrhage in pigs. Characterization of cerebrospinal fluid dynamics and the effects of fibrinolytic treatment. Stroke. 1997;28(1):141–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Holly E. Hinson
    • 1
  • Eric Melnychuk
    • 2
  • John Muschelli
    • 2
  • Daniel F. Hanley
    • 2
  • Issam A. Awad
    • 3
  • Wendy C. Ziai
    • 1
  1. 1.Division of Neurosciences Critical CareJohns Hopkins University School of MedicineBaltimoreUSA
  2. 2.Division of Brain Injury Outcomes, Department of NeurologyJohns Hopkins University School of MedicineBaltimoreUSA
  3. 3.Section of NeurosurgeryUniversity of Chicago Medical CenterChicagoUSA

Personalised recommendations